| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ALVR | Common Stock | Sale | -$26K | -5.11K | -0.49% | $5.08 | 1.03M | Jan 19, 2023 | Direct | F1, F2 |
| transaction | ALVR | Common Stock | Sale | -$7.34K | -1.43K | -0.14% | $5.14 | 1.03M | Jan 20, 2023 | Direct | F1, F3 |
| holding | ALVR | Common Stock | 16.7M | Jan 19, 2023 | Shares held by ElevateBio LLC | F4 |
| Id | Content |
|---|---|
| F1 | Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1. |
| F2 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.94 to $5.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F3 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.05 to $5.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F4 | Shares held by ElevateBio. The Reporting Person is a director and Chief Financial Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Officer Title: President and Chief Financial Officer